BioSpace News Archive

CHI Franciscan’s St. Francis Hospital in Federal Way, Washington is expanding high quality, innovative surgical care with a spinal robotic surgery platform that combines robotics and navigation software—the first of its kind in King County.

Vital is hosting must-attend events featuring customer insights, innovation and discussions around its powerful Enterprise Imaging solution

The MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the only hospital in Southern California — and one of only four sites in all of California — participating in the Dual Epicardial and Endocardial Procedure clinical trial.

Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved BARHEMSYS® (amisulpride injection) for the prevention and treatment of PONV in adult patients.

NanoView Biosciences, Inc. and Izasa Scientific announced an exclusive distribution agreement for NanoView’s ExoView® platform in Spain and Portugal.

President & CEO Nick Westfall of VITAS® Healthcare, the nation’s leading provider of end-of-life care, has been named one of seven new members of the board of directors of the National Hospice and Palliative Care Organization, effective January 22, 2020.

Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase shares of its common stock in an underwritten public offering.

CVS Health Corporation announced that Eva Boratto, Executive Vice President and Chief Financial Officer, and Alan Lotvin, Executive Vice President and President of CVS Caremark, will be participating in a fireside chat with investors at the Barclays Global Healthcare Conference on March 12, 2020, at approximately 8:30 a.m. ET.

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, reported financial results for the quarter and year ended December 31, 2019.

Tumor outcomes results from two-year follow-up of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese to be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium